Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Endocardial transcription factor HAND2 orchestrates hypoxic and TGF-β signaling to modulate coronary artery formation
Huijuan Wang, Haosheng Zhang, Leiyin Zheng, Peihan Zhang, Yuqian Wang, Sijia Ding, Wenping Liu, Yuanming Cheng, Zhongzhou Yang, Wen Luo
Huijuan Wang, Haosheng Zhang, Leiyin Zheng, Peihan Zhang, Yuqian Wang, Sijia Ding, Wenping Liu, Yuanming Cheng, Zhongzhou Yang, Wen Luo
View: Text | PDF
Research Article Cardiology Vascular biology

Endocardial transcription factor HAND2 orchestrates hypoxic and TGF-β signaling to modulate coronary artery formation

  • Text
  • PDF
Abstract

The endocardium is a major source of coronary angiogenesis and arterialization, through coordinated cell fate transition and migration. However, the transcriptional regulatory network synchronizing cell fate determination and movement remains unclear. Here, we identified transcription factor HAND2 as a key candidate for coronary vascular formation. Endocardial deletion of Hand2 in mice disrupted arterial-venous networks and stunted coronary arteries, paralleling a ventricular noncompaction phenotype. Moreover, deletion of Hand2 produced excessive tip cells with defective movement. RNA-seq analysis revealed enhanced hypoxic metabolic activation but declined TGF-β/p38MAPK–dependent endothelial-mesenchymal transition. In contrast, genetic inhibition of the core hypoxic regulators or pharmaceutical administration of TGF-β2 partially recovered the coronary arterial defects in Hand2 mutants. Furthermore, HAND2 was found to directly bind to promoters of the target genes, harmonizing cell migration and cell fate transition. These findings pinpoint HAND2 as an essential regulator of the endocardial transcriptional regulatory network for coronary arterialization and provide potential therapeutic targets for coronary artery diseases.

Authors

Huijuan Wang, Haosheng Zhang, Leiyin Zheng, Peihan Zhang, Yuqian Wang, Sijia Ding, Wenping Liu, Yuanming Cheng, Zhongzhou Yang, Wen Luo

×

Figure 2

Hand2 is required for normal cardiovascular development.

Options: View larger image (or click on image) Download as PowerPoint

Hand2 is required for normal cardiovascular development.
(A) Experiment...
(A) Experimental strategy for Hand2 deletion in cardiac endothelium. (B) Costaining of HAND2 and ERG of E15.5 WT and Hand2-EKO sections showing Hand2 deletion efficiency. The yellow arrows indicate ERG+HAND2+ ECs in the endocardium in controls; the white arrows represent ERG+HAND2– ECs in the endocardium in Hand2-EKO mice, which demonstrate the gene deletion efficiency. (C) Quantification of HAND2+ERG+ cells in compact myocardium ECs (CM ECs) and trabecular myocardium ECs (TM ECs). n = 4 hearts per group. (D) Bright-field images of E15.5 gross embryos and hearts showing defective embryogenesis. (E) H&E staining showing marked thinning of ventricular myocardial wall and hypertrabeculation in Hand2-EKO hearts at E15.5. n = 3 hearts per group. (F and G) Immunostaining of EMCN showing decreased myocardial thickness in E15.5 Hand2-EKO hearts and (G) quantifications. n = 5 hearts per group. (H and I) Whole-mount staining of E15.5 coronary veins showing decreased density, diameter of veins, and ERG+ cell numbers with (I) quantification analysis. n = 4 hearts per group. (J and K) Confocal images showing absence of normal coronary artery formation and extension in E15.5 Hand2-EKO hearts and (K) quantifications. n = 4 hearts per group. Data represent mean ± SEM. Statistical significance was assessed using multiple unpaired 2-tailed t tests with Benjamini-Krieger-Yekutieli FDR correction for (C) and (G) and unpaired 2-tailed Student’s t tests for (I and K). ***P < 0.0001. Scale bars: 200 μm (B, E, F, H and J); 500 μm (D).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts